AIRSHIGH SIGNALFINANCIAL10-K

AIRS experienced a significant operational deterioration with revenue declining 15.8% while operating cash flow collapsed substantially and the company deepened its losses.

The combination of meaningful revenue decline and dramatically reduced operating cash flow generation suggests fundamental business challenges beyond normal market fluctuations. The company's shift from highlighting "predictable and recurring revenue" and "100% private pay upfront" in prior language to removing these confidence-building statements indicates management may be facing demand headwinds in their elective cosmetic procedures business.

Comparing 2026-03-31 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

AIRS showed broad-based financial deterioration with revenue declining 15.8% to $151.8 million while net losses widened to $11.7 million from $8.3 million despite reduced SG&A spending. Operating cash flow generation fell dramatically from $11.3 million to just $3.1 million, while capital expenditures dropped significantly from $14.0 million to $2.4 million, suggesting possible investment pullbacks. The balance sheet improved modestly with debt reduction and higher stockholders' equity, but the operational cash generation weakness represents a concerning development for this elective healthcare services company.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-82.8%
$14.0M→$2.4M

Capex reduced 82.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-72.7%
$11.3M→$3.1M

Operating cash flow fell 72.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-41.4%
-$8.3M→-$11.7M

Net income declined 41.4% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
-23.8%
$130.7M→$99.6M

Liabilities reduced 23.8% — deleveraging improves balance sheet strength and financial flexibility.

Total Debt
Balance Sheet
-19.6%
$69.7M→$56.0M

Debt reduced 19.6% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
-16.9%
$98.9M→$82.2M

SG&A reduced 16.9% — improved cost efficiency or headcount reduction improving operating margins.

Revenue
P&L
-15.8%
$180.3M→$151.8M

Revenue softened 15.8% — monitor whether this is cyclical or structural.

Total Assets
Balance Sheet
-10.8%
$210.0M→$187.3M

Total assets contracted 10.8% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
+10.6%
$79.3M→$87.7M

Equity base grew 10.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-14
ADDED
AirSculpt Smooth uses an advanced cellulite removal tool, which is cleared by the Food and Drug Administration ("FDA") to target cellulite on the buttocks and thighs.
We deliver our body contouring procedures through a nationwide footprint of 31 centers across 20 U.S.
For the year ended December 31, 2025, we generated $151.8 million of revenue compared to $180.4 million for the year ended December 31, 2024, which represents a decline of approximately 15.8%.
Our Competitive Strengths We attribute our success to the following strengths that differentiate us from our competitors: Trusted Brand Redefining Body Contouring The AirSculpt method was created to offer patients a gentler alternative to traditional fat removal procedures with transformative results delivered in a luxurious, spa-like environment.
design patent application, one pending Canada utility patent application, and one pending U.K.
+7 more — sign up free →
REMOVED
AirSculpt Smooth uses an advanced cellulite removal tool, which is FDA-cleared to target cellulite on the buttocks and thighs.
We deliver our body contouring procedures through a growing, nationwide footprint of 32 centers across 20 U.S.
The value proposition provided by our services results in exceptional unit-level economics, which in turn helps to support predictable and recurring revenue and attractive cash flow.
Additionally, we require 100% private pay upfront and, therefore, face no reimbursement risk.
Under the stewardship of our founder and Executive Chairman of our board of directors, Dr.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →